Nasdaq btai

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning ...

Nasdaq btai. By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics ...

On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days.

Good news is that we have both equity as well as potential debt option in addition to, as I mentioned previously, partnering, which can be outside the U.S. for Alzheimer’s-related agitation ...NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics Inc Follow Share $3.93 After Hours: $3.90 (0.76%) -0.030 Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Ardelyx Inc …NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”), a commercial-stage biopharmaceutical company ...BioXcel Therapeutics (NASDAQ:BTAI), a biopharma company based in Connecticut, leverages AI and machine learning to develop innovative treatments for central nervous system and immuno-oncology ...NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...

The FDA-approved Igalmi from BioXcel Therapeutics (NASDAQ:BTAI) for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults has garnered attention.BioXcel Therapeutics, Inc. (BTAI.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock BioXcel Therapeutics, ...Mar 9, 2023 · BioXcel Therapeutics will host a conference call and webcast at 8:30 a.m. ET on March 9 to discuss its fourth quarter and full-year 2022 financial results and provide an update on recent ... To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.Nov 19, 2023 · BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) – Equities research analysts at HC Wainwright reduced their FY2023 EPS estimates for BioXcel Therapeutics in a research note issued to investors on Wednesday, November 15th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($6.63) per share for the year, down from […] Find the latest SEC Filings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”), a commercial-stage biopharmaceutical company ...BTAI U.S.: Nasdaq. BioXcel Therapeutics Inc. Watchlist. Alert. NEW. Set a price ... Real-time last sale data for U.S. stock quotes reflect trades reported through ...BioXcel Therapeutics will host a conference call and webcast May 9, 2022, at 8:30 a.m., ET, to discuss its first quarter 2022 financial results and provide an update on recent operational ...Track BioXcel Therapeutics Inc (BTAI) Stock Price, Quote, latest community messages, chart, news and other stock related information.BTAI | Informative NASDAQ:BTAI Technical Analysis for NASDAQ:BTAI : If the price of BTAI breaks above the bullish line of $11.61, it may indicate a bullish signal, suggesting …

Iai stock.

Which BioXcel Therapeutics insiders have been selling company stock? The following insiders have sold BTAI shares in the last 24 months: Frank Yocca ($1,519,394.65), Javier Rodriguez ($48,766.20), Krishnan Nandabalan ($2,029,310.26), Richard I Steinhart ($176,488.00), and Vimal Mehta ($2,029,075.00).NEW HAVEN, Conn., June 22, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. BioXcel Therapeutics, Inc. Common Stock (BTAI) Pre-Market Stock Quotes - Nasdaq ... NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence ...BioXcel Therapeutics Inc stock price live 3.79, this page displays NASDAQ BTAI stock exchange data. View the BTAI premarket stock price ahead of the market session or assess the after hours quote.BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...BTAI BTAI PRE-MARKET QUOTE BTAI LATEST PRE MARKET TRADES. ... Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Jun 2, 2023 · Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy recommendation. Analyst Price Forecast Suggests 586.04% Upside. As of ... Nasdaq | BTAI U.S.: Nasdaq BioXcel Therapeutics Inc. Watch NEW Set a price target alert Open Last Updated: Nov 17, 2023 at 10:39 a.m. EST Real time quoteA great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM BioXcel Therapeutics, Inc. (BTAI). NASDAQ: BTAI · IEX Real-Time Price · USD.A great week that adds to BioXcel Therapeutics, Inc.'s (NASDAQ:BTAI) one-year returns, institutional investors who own 48% must be happy (Simply Wall St.) Dec-22-22 07:00AM BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.25%.

NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

Nov 24, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ... 21 Nov 2023 ... Find the latest dividend history for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BTAI STOCK Price - BioXcel Therapeutics Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary ...The SEC requires all publicly traded companies, foreign and domestic, to disclose financial condition, operating results, management compensation, and other ...Aug 16, 2022 · The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ...

Money market fund highest yield.

Csx stock dividend.

NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ...NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...Find the latest Earnings Report Date for TG Therapeutics, Inc. Common Stock (TGTX) at Nasdaq.com.May 3, 2022 · NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ... Back to BTAI Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.The 5 analysts offering 12-month price forecasts for BioXcel Therapeutics Inc have a median target of 11.00, with a high estimate of 18.00 and a low estimate of 4.00. The median estimate ...The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ...BioXcel Therapeutics Inc. 4.13. Delayed Data. As of Nov 17. -0.12 / -2.82%. Today’s Change. 2.23. Today ||| 52-Week Range. 34.13.Oct 31, 2023 · NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ... ….

Nov 14, 2022 · By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics ... May 19, 2021 · NEW HAVEN, Conn., May 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ... The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ...NASDAQ: BTAI ® BXCL701 Key Opinion Leader Day February 21, 2023 ... | April 10, 2023NEW HAVEN, Conn., May 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Find the latest on option chains for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.Oct 4, 2023 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ... BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information. Instantly BTAI was in red as seen at the end of in last trading. With action -20.12%, the performance over the past five days has been red. The drop to weekly highs of 5.62 on Friday, 11/17/23 subtracted -2.82% to the stock’s daily price. Nasdaq btai, NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ..., About Insider Activity. Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company ... , BioXcel Therapeutics, Inc. Common Stock (BTAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. , 21 Nov 2023 ... Find the latest dividend history for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com., Nov 30, 2023 · The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023. The analyst firm set a price target for 11.00 expecting BTAI ... , BioXcel Therapeutics, Inc. Common Stock (BTAI) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. , NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ..., NEW HAVEN, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ..., NEW HAVEN, Conn., May 20, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ..., NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ..., Which BioXcel Therapeutics insiders have been selling company stock? The following insiders have sold BTAI shares in the last 24 months: Frank Yocca ($1,519,394.65), Javier Rodriguez ($48,766.20), Krishnan Nandabalan ($2,029,310.26), Richard I Steinhart ($176,488.00), and Vimal Mehta ($2,029,075.00)., BioXcel Therapeutics (NASDAQ:BTAI) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its Tranquility II clinical trial.. According to a ..., BioXcel Therapeutics ( NASDAQ: BTAI) is a biopharmaceutical firm located in Connecticut, United States. The company's objective is to market and develop therapies for the treatment of central ..., add_box. NEW HAVEN, Conn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ..., The big shareholder groups in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely ..., OnkosXcel is a subsidiary of BioXcel Therapeutics, Inc. (Nasdaq: BTAI). This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, ..., BioXcel Therapeutics ( NASDAQ:BTAI ) Third Quarter 2023 Results Key Financial Results Net loss: US$50.5m (loss widened... Simply Wall St.•17 days ago., Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing., BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ..., BioXcel Therapeutics Inc (NASDAQ:BTAI) showed a performance of 51.72% in past 30-days. Number of shares sold short was 5.81 million shares which calculate 1 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $10.50 to the stock, which implies a rise of 58.1% to its current value., NEW HAVEN, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ..., BioXcel Therapeutics Inc stock price live 3.79, this page displays NASDAQ BTAI stock exchange data. View the BTAI premarket stock price ahead of the market session or assess the after hours quote., NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ..., BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ …, Headquartered in New Haven, Connecticut, Bioxcel Therapeutics (NASDAQ:BTAI) might not seem that impressive of an enterprise at first glance.Since the beginning of this year, BTAI slipped almost 1% ..., On November 14, 2023, BioXcel Therapeutics Inc ( NASDAQ:BTAI) released its 8-K filing, announcing strategic advancements and financial results for the third quarter ended September 30, 2023. The ..., BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary ..., BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information. Instantly BTAI was in red as seen at the end of in last trading. With action -20.12%, the performance over the past five days has been red. The drop to weekly highs of 5.62 on Friday, 11/17/23 subtracted -2.82% to the stock’s daily price., NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that..., BioXcel Therapeutics Inc Follow Share $3.93 After Hours: $3.90 (0.76%) -0.030 Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Ardelyx Inc …, Apr 28, 2023 · 586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... , BioXcel Therapeutics ( NASDAQ:BTAI ) Third Quarter 2023 Results Key Financial Results Net loss: US$50.5m (loss widened... Simply Wall St.•17 days ago., BioXcel Therapeutics ( NASDAQ: BTAI ), based in Connecticut, develops treatments for CNS and cancer disorders, including FDA-approved Igalmi (marketed sublingual dexmedetomidine) and BXCL701 for ...